Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | GPR183 | P32249 | 2/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.36 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5429703 | 0.79 | TNFRSF1A (0.57) | SMN1; SMN2KMT2AKDM4EGAAMEN1 | |
| SCHEMBL5436272 | 0.78 | MAOB (0.50) | SMN1; SMN2LMNAHTR2BNTSR1MAPT | |
| SCHEMBL1481645 | 0.78 | MIF (0.53) | SMN1; SMN2GPR183DGAT1KMT2AKDM4E | |
| SCHEMBL1481643 | 0.78 | MIF (0.53) | SMN1; SMN2GPR183DGAT1KMT2AKDM4E | |
| SCHEMBL17157715 | 0.76 | SMN1; SMN2 (0.54) | SMN1; SMN2GPR183DGAT1KMT2AGAA | |
| SCHEMBL17157713 | 0.76 | SMN1; SMN2 (0.54) | SMN1; SMN2GPR183DGAT1KMT2AGAA | |
| SCHEMBL14880180 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2GPR183KMT2AKDM4EMEN1 | |
| SCHEMBL14880179 | 0.75 | SMN1; SMN2 (0.50) | SMN1; SMN2GPR183KMT2AKDM4EMEN1 | |
| SCHEMBL5426867 | 0.74 | HTR2B (0.48) | SMN1; SMN2LMNAHTR2BMAPT | |
| SCHEMBL3118702 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2GPR183DGAT1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2617709-B1 | Guanidine derivatives as antiviral agents | BIOTRON LTD (AU) | 2022-11-16 | — | — | EP | claimed |
| US-10472332-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2019-11-12 | — | — | US | claimed |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2017-09-14 | — | — | US | claimed |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2015-11-05 | — | — | US | claimed |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | GAGE PETER WILLIAM (AU) | 2013-02-07 | — | — | US | claimed |
| US-20070099968-A1 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2007-05-03 | — | — | US | claimed |
| EP-1646371-A2 | ANTIVIRAL COMPOUNDS AND METHODS | Biotron Limited (AU) | 2006-04-19 | — | — | EP | claimed |
| WO-2004112687-A2 | ANTIVIRAL ACYLGUANIDINE COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2004-12-29 | — | — | WO | claimed |
| EP-2617709-B1 | Guanidine derivatives as antiviral agents | BIOTRON LTD (AU) | 2022-11-16 | — | — | EP | disclosed |
| US-11192863-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2021-12-07 | — | — | US | disclosed |
| US-10683263-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2020-06-16 | — | — | US | disclosed |
| US-10472332-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2019-11-12 | — | — | US | disclosed |
| EP-2826770-B1 | ACYLGUANIDINE COMPOUNDS WITH ANTIVIRAL ACTIVITY | BIOTRON LTD (AU) | 2018-09-12 | — | — | EP | disclosed |
| US-20170362170-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTRON LTD (AU) | 2017-12-21 | — | — | US | disclosed |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | GAGE PETER WILLIAM (AU) | 2013-02-07 | — | — | US | disclosed |
| US-20100254942-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | BIOTRON LIMITED (AU) | 2010-10-07 | — | — | US | disclosed |
| US-20090099239-A1 | Antiviral Compounds and Methods | BIOTRON LIMITED (AU) | 2009-04-16 | — | — | US | disclosed |
| US-20070099968-A1 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2007-05-03 | — | — | US | disclosed |
| EP-1646371-A2 | ANTIVIRAL COMPOUNDS AND METHODS | Biotron Limited (AU) | 2006-04-19 | — | — | EP | disclosed |
| WO-2004112687-A2 | ANTIVIRAL ACYLGUANIDINE COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254942-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | HAVCR2, HCCS, EIF2AK2 | SMN1; SMN2 4031/4885GPR183 3406/4885DGAT1 1012/4885 |
| US-11192863-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | SMN1; SMN2 2555/4885GPR183 2033/4885DGAT1 936/4885 |
| US-10683263-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | SMN1; SMN2 2243/4885GPR183 2742/4885DGAT1 1163/4885 |
| US-10472332-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | SMN1; SMN2 2555/4885GPR183 2033/4885DGAT1 936/4885 |
| US-20070099968-A1 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | SMN1; SMN2 2257/4885GPR183 2404/4885DGAT1 850/4885 |
| US-20170362170-A1 | HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS | HAVCR2, HCCS, EIF2AK2 | SMN1; SMN2 4031/4885GPR183 3406/4885DGAT1 1012/4885 |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | MAVS, ZC3HAV1, EIF2AK2 | SMN1; SMN2 2555/4885GPR183 2033/4885DGAT1 936/4885 |
| US-20090099239-A1 | Antiviral Compounds and Methods | MAVS, ZC3HAV1, EIF2AK2 | SMN1; SMN2 2243/4885GPR183 2742/4885DGAT1 1163/4885 |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | ZC3HAV1, MAVS, EIF2AK2 | SMN1; SMN2 2399/4885GPR183 2403/4885DGAT1 871/4885 |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | ZC3HAV1, MAVS, EIF2AK2 | SMN1; SMN2 2399/4885GPR183 2403/4885DGAT1 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.